Pooled data from meta-analyses have shown a consistent increase in both creatine kinase–myoglobin binding (CK-MB) (SMD, 0.54 U/L; 95% CI, 0.39–0.69; p < 0.001) and myoglobin (SMD, 0.80 U/L; 95% CI, 0.57–1.03, p < 0.001) among patients with severe forms of COVID-19. The gene discussed is MB; the disease is COVID-19.